FTC Sues to Block Amgen’s $28B Horizon Therapeutics Deal
The FTC said the acquisition would allow Amgen to entrench Horizon’s monopoly on medications for thyroid eye disease and chronic refractory gout.
Enter the email associated with your account and we'll send you a link to reset your password.